| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1038301796 |
| P356 | DOI | 10.1038/LEU.2008.396 |
| P932 | PMC publication ID | 2763584 |
| P698 | PubMed publication ID | 19277049 |
| P5875 | ResearchGate publication ID | 24192154 |
| P2093 | author name string | W I Bensinger | |
| P2860 | cites work | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 |
| The role of immunomodulatory drugs in multiple myeloma | Q33359947 | ||
| Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma | Q74490573 | ||
| Mixed hematopoietic chimerism after hematopoietic stem cell allografts | Q74616585 | ||
| Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation | Q76381510 | ||
| Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma | Q77631346 | ||
| Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning | Q78834266 | ||
| Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning | Q79421927 | ||
| Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study | Q79811602 | ||
| Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 | ||
| Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma | Q80121138 | ||
| A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma | Q81606574 | ||
| Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma | Q82192536 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| A comparison of allografting with autografting for newly diagnosed myeloma | Q34577703 | ||
| Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy | Q35848356 | ||
| Immunotherapy of multiple myeloma: the start of a long and tortuous journey | Q36689152 | ||
| Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. | Q36831384 | ||
| Comparison of twin and autologous transplants for multiple myeloma | Q36975837 | ||
| A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97 | Q37088191 | ||
| Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma | Q37523265 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. | Q43573096 | ||
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 | ||
| Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma | Q44071975 | ||
| Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma | Q44139126 | ||
| Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality | Q44189564 | ||
| Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation | Q44386867 | ||
| Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning | Q44418467 | ||
| Single versus double autologous stem-cell transplantation for multiple myeloma. | Q44706045 | ||
| Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. | Q45076113 | ||
| Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival | Q46253134 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. | Q46640315 | ||
| Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial | Q46745193 | ||
| High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe | Q46795068 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 | ||
| Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. | Q50983345 | ||
| Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. | Q53243787 | ||
| Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. | Q53510360 | ||
| Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. | Q54657115 | ||
| Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides | Q56994227 | ||
| Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study | Q56995088 | ||
| High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial | Q57780128 | ||
| Relationship Between Depth of Response and Outcome in Multiple Myeloma | Q60976709 | ||
| Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience | Q69571696 | ||
| Graft-versus-myeloma effect: proof of principle | Q70903400 | ||
| Graft-versus-myeloma effect in two cases | Q71060552 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Graft-versus-myeloma effect | Q71264400 | ||
| Syngeneic marrow transplantation in patients with multiple myeloma | Q71702757 | ||
| High-dose intravenous melphalan for plasma-cell leukaemia and myeloma | Q72562480 | ||
| Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation | Q73071994 | ||
| Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy | Q73586012 | ||
| Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial | Q74453880 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 442-448 | |
| P577 | publication date | 2009-01-29 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Role of autologous and allogeneic stem cell transplantation in myeloma | |
| P478 | volume | 23 |
| Q37810116 | Adoptive T-cell therapy for B-cell malignancies |
| Q88528165 | Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma |
| Q24198198 | Allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed Multiple Myeloma |
| Q44021179 | Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up |
| Q57289945 | Bone marrow transplantation generates T cell-dependent control of myeloma in mice |
| Q42846395 | Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience |
| Q40719473 | Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy |
| Q36520769 | Concerns of stem cell transplant patients during routine ambulatory assessment |
| Q37761370 | Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. |
| Q47834399 | Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation |
| Q26771331 | Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity |
| Q39527323 | Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma |
| Q90156172 | Immunotherapy of multiple myeloma |
| Q39425529 | In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review |
| Q64937145 | Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. |
| Q37653639 | Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma |
| Q36209857 | Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan |
| Q84716328 | Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! |
| Q27334339 | Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling |
| Q37800884 | The Belgian 2010 consensus recommendations for the treatment of multiple myeloma |
| Q26471825 | The effects of allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed multiple myeloma |
| Q47583403 | The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. |
| Q26785735 | Top Information Need Priorities of Older Adults Newly Diagnosed With Active Myeloma |
| Q35172500 | Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis |
Search more.